We are live on ! Find out more
LKFT

Lakefront Biotherapeutics American Depositary Shares

81 hedge funds and large institutions have $450M invested in Lakefront Biotherapeutics American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding in top 10

Funds holding in top 10: 15 (+4)

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

1.95% more ownership

Funds ownership: 11.1%13.05% (+1.9%)

10% less capital invested

Capital invested by funds: $501M → $450M (-$51.3M)

25% less funds holding

Funds holding: 10881 (-27)

42% less call options, than puts

Call options by funds: $21.8M | Put options by funds: $37.8M

63% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 41

Holders
81
Holders Change
-27
Holders Change %
-25%
% of All Funds
1.42%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.09%
New
15
Increased
31
Reduced
19
Closed
41
Calls
$21.8M
Puts
$37.8M
Net Calls
-$16M
Net Calls Change
-$6.54M
Name Holding Trade Value Shares
Change
Change in
Stake
EC
1
EcoR1 Capital
California
$82M +$92.5M +1,558,749 New
BI
2
BVF Inc
California
$58.9M +$66.5M +1,119,733 New
O
3
OrbiMed
New York
$38.1M +$29.2M +492,552 +213%
6CM
4
683 Capital Management
New York
$36.9M +$39.7M +668,098 +2,005%
Citadel Advisors
5
Citadel Advisors
Florida
$26.3M +$2.79M +47,039 +10%
BlackRock
6
BlackRock
New York
$20.5M -$1.03M -17,416 -4%
JP Morgan Chase
7
JP Morgan Chase
New York
$15.4M +$17.3M +291,819 +65,138%
PM
8
Prosight Management
Texas
$13.2M +$10.6M +178,680 +248%
SCM
9
Stonepine Capital Management
Oregon
$12.8M +$14.5M +244,205 New
SCM
10
Sio Capital Management
New York
$11.8M +$13.3M +224,719 New
Parallax Volatility Advisers
11
Parallax Volatility Advisers
California
$11.5M +$12.9M +217,924 New
Millennium Management
12
Millennium Management
New York
$11.1M +$3.84M +64,696 +44%
Hudson Bay Capital Management
13
Hudson Bay Capital Management
Connecticut
$8.15M +$1.78M +30,000 +24%
Morgan Stanley
14
Morgan Stanley
New York
$7.49M -$2.02M -34,053 -19%
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$7.2M +$4.14M +69,710 +104%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$6.67M +$4.76M +80,145 +172%
Norges Bank
17
Norges Bank
Norway
$6.31M
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$6.2M -$35.3M -594,256 -83%
SCM
19
Soleus Capital Management
Connecticut
$6.07M +$6.84M +115,300 New
LP
20
LMR Partners
United Kingdom
$5.26M +$5.94M +100,000 New
Fidelity Investments
21
Fidelity Investments
Massachusetts
$4.59M -$30.7M -517,259 -86%
Voloridge Investment Management
22
Voloridge Investment Management
Florida
$4.59M -$34.3K -578 -0.7%
IC
23
Ikarian Capital
Texas
$4.54M -$6.72M -113,135 -57%
SC
24
Sessa Capital
New York
$4.31M
DCM
25
DAFNA Capital Management
California
$4.09M

LKFT Hedge Fund Activity: Q3 2021 in Review

81 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2021, worth a combined $450M — down 10% from $501M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of LKFT and 15 opened new positions — a net loss of 26 holders — while 19 trimmed existing stakes and 31 added.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $92.5M. The largest seller was Capital International Investors, exiting entirely with an estimated $119M sold.

  • 81 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2021, down from 108 in Q2 2021.
  • Funds reported $450M of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2021, down 10% quarter-over-quarter.
  • 15 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2021 and 41 closed out, a net change of -26 holders.
  • The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2021 was EcoR1 Capital, an estimated $92.5M added.
  • The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2021 was Capital International Investors, an estimated $119M sold.

Based on aggregated 13F filings for Q3 2021.